-
Big Movers in Focus: Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ), 21Vianet Group (NASDAQ:VNET), RXi Pharmaceuticals (NASDAQ:RXII), BlackBerry (NASDAQ:BBRY), SLM Corporation (NASDAQ:SLM)
TheStreet upgraded shares of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) from a hold rating to a buy rating in a research report released on Tuesday morning. On Tuesday shares of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) closed at $169.99. Company’s sales growth for last 5 years was 55.60% and EPS growth for next…
-
Notable Moves: 500.com Limited (NYSE:WBAI), Kinder Morgan (NYSE:KMI), The Estee Lauder Companies Inc. (NYSE:EL), Schweitzer-Mauduit International Inc. (NYSE:SWM), RXi Pharmaceuticals (NASDAQ:RXII)
500.com Limited (NYSE: WBAI) announced that its board of directors approved a share repurchase program, effective immediately. Under the program, the Company is authorized to repurchase up to US$30 million worth of outstanding American depositary shares (“ADSs”) from time to time depending on market conditions and other factors as well as subject to relevant rules…
-
Market Movers: Niska Gas Storage Partners LLC (NYSE:NKA), Wright Medical Group Inc. (NASDAQ:WMGI), Oracle (NYSE:ORCL), RXi Pharmaceuticals (NASDAQ:RXII), Newtek Business Services (NASDAQ:NEWT)
Niska Gas Storage Partners LLC (NYSE:NKA) reported on 2 February 2015, its financial results for the quarter and nine months ended December 31, 2014. Adjusted EBITDA (as defined below) for Niska’s quarter ended December 31, 2014 was $9.4 million, compared to $37.0 million for the quarter ended December 31, 2013. Adjusted EBITDA was $48.0 million…
-
Investors Alert: RXi Pharmaceuticals Corporation (NASDAQ:RXII), Biota Pharmaceuticals (NASDAQ:BOTA), International Paper Company (NYSE:IP), Natural Resource Partners LP (NYSE:NRP), Tucows Inc. (NASDAQ:TCX)
On 3 February, RXi Pharmaceuticals Corporation (NASDAQ:RXII) announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for the delivery of double stranded siRNAs (21 to 23 nucleotides in length) across the blood-retina barrier (e.g. topical or systemic delivery) for the treatment of wet age-related macular degeneration or…
-
Biotech Volatile Stocks: RXi Pharmaceuticals Corporation (NASDAQ:RXII), Kite Pharma (NASDAQ:KITE), EPIRUS Biopharmaceuticals (NASDAQ:EPRS), Ohr Pharmaceutical (NASDAQ:OHRP), Cellular Biomedicine (NASDAQ:CBMG)
On 5 February, RXi Pharmaceuticals Corporation (NASDAQ: RXII), announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone™ with Hapten Pharmaceuticals, LLC. On Tuesday shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) closed at $1.26. On 3 February, Kite Pharma, Inc., (NASDAQ:KITE) announced the appointments of Salah D. Kivlighn, Ph.D.,…
-
Biotech Gainers: Genetic Technologies Limited (NASDAQ:GENE), Esperion Therapeutics (NASDAQ:ESPR), Theravance Inc. (NASDAQ:THRX), RXi Pharmaceuticals Corporation (NASDAQ:RXII), Recro Pharma (NASDAQ:REPH)
Genetic Technologies Limited (NASDAQ:GENE) on 29 January announced that up to 6 new breast diagnosis/treatment centers are expected to begin offering BREVAGenplus? to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging center customers expected to follow later in calendar…
-
Traders Should Watch: Array BioPharma (NASDAQ:ARRY), Envivio (NASDAQ:ENVI), Kyocera Corp. (NYSE:KYO), General Finance Corporation (NASDAQ:GFN), RXi Pharmaceuticals Corporation (NASDAQ:RXII)
Array BioPharma Inc. (NASDAQ:ARRY) announced that it has reached a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development. On Friday shares of Array BioPharma, Inc. (NASDAQ:ARRY) closed at $7.11. Company’s sales growth for last 5 years was 11.00% and EPS growth for…
-
Top Movers: Cliffs Natural Resources Inc. (NYSE:CLF), RXi Pharmaceuticals Corporation (NASDAQ:RXII), Ball Corporation (NYSE:BLL), Accuray Incorporated (NASDAQ:ARAY), KKR & Co. L.P. (NYSE:KKR)
Cliffs Natural Resources (NYSE:CLF) had its price objective trimmed by JPMorgan Chase & Co. from $10.00 to $8.00 in a research report released on Monday morning. JPMorgan Chase & Co. currently has a neutral rating on the stock. On Thursday shares of Cliffs Natural Resources Inc. (NYSE:CLF) closed at $8.59. Company’s sales growth for last…
-
Healthcare Bulls: The Medicines Company (NASDAQ:MDCO), RXi Pharmaceuticals Corporation (NASDAQ:RXII), Retractable Technologies (NYSEMKT:RVP), Eagle Pharmaceuticals Inc. (NASDAQ:EGRX), Agile Therapeutics (NASDAQ:AGRX)
The Medicines Company (NASDAQ:MDCO) on 7 January announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2022, an increase from the $300 million in aggregate principal amount previously announced. On Wednesday shares of The Medicines Company (NASDAQ:MDCO) closed at $26.02. Company’s sales growth…